Search
3 articles for “Adverse immune reactions”
-
SiRNA-Based Multivalent Vaccines: A Systematic Review of Potential Risks, Benefits, and Future Applications
Abstract: Background: Small interfering RNA (SiRNA) technology represents a promising innovation in vaccine development, especially for multivalent vaccines that can target multiple pathogens or antigenic variants simultaneously. siRNA-based vaccines offer a unique mechanism to induce specific immune responses, presenting an adaptable and potentially powerful tool for tackling infectious diseases and cancer. Methods: This systematic review synthesizes recent studies on siRNA multivalent vaccines, focusing on their immunogenicity, safety, and effectiveness. We reviewed …
Published in International Journal of Vaccines · Vol. 2, Issue 1, 2025 · pp. 43–49 Read article
-
Impact of Vaccine Awareness Campaigns on Pharmacovigilance Reporting and Public Safety Monitoring
Abstract: Vaccination programs have significantly contributed to the reduction of infectious diseases worldwide; however, their success is closely tied to public confidence and robust safety monitoring systems. Pharmacovigilance plays a critical role in identifying, assessing, and preventing adverse events following immunization (AEFI). In recent years, vaccine awareness campaigns have emerged as a pivotal strategy to improve public knowledge, reduce vaccine hesitancy, and enhance reporting of adverse drug reactions (ADRs). This review …
Published in International Journal of Vaccines · Vol. 3, Issue 2, 2026 · pp. 1–14 Read article
-
The Burden of Empirical Therapy: Analyzing the Predominance of Broad-Spectrum Antibiotic Usage in Lower Respiratory Tract Infections
Abstract: Lower respiratory tract infections (LRTIs) remain one of the leading causes of morbidity and hospitalization worldwide, particularly among older adults, immunocompromised individuals, and patients with chronic respiratory disorders. These infections include conditions such as community-acquired pneumonia, hospital-acquired pneumonia, bronchitis, and acute infective exacerbations of chronic lung disease, all of which often require rapid clinical intervention. Because microbiological confirmation of the causative pathogen frequently takes 48–72 hours, clinicians generally initiate empirical …
Published in International Journal of Antibiotics · Vol. 3, Issue 2, 2026 Read article